Pelvic Congestion Syndrome denials in California external review

In the California DMHC record, independent physician reviewers decided 24 published external-review cases involving pelvic congestion syndromeand overturned the plan’s denial in 83.3%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
24
2010–2025
Overturned
83.3%
20 denials reversed

What the insurer actually argued

Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
Reason givenDecisionsOverturned
Experimental/Investigational
The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument.
21
90.5%
Medical Necessity
The plan said the care wasn’t medically necessary. The most common fight, and the most winnable.
3
33.3%
Typical time to a decision
13 days
Most land between 7 and 21 days
Handled as urgent
54.2%
Expedited when a delay would cause harm

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for ovarian and inner iliac vein embolization. Findings: The physician reviewer found that In a systematic review of ovarian vein embolization in 21 prospective case series and one randomized trial including 1,308 women, Daniels and colleagues reported that early substantial relief from pain was observed in approximately 75% of women undergoing embolization, and generally increased over time and was sustained. The authors concluded that embolization appears to provide symptomatic relief of chronic pelvic pain in the majority of women and is safe.
Experimental/Investigational · 2022 · IMR EI22-38192
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for (1) ovarian vein embolization and (2) sclerotherapy with possible stent placement. Pelvic congestion syndrome is an underreported condition of pelvic pain, heaviness, and fatigue in women and characterized by engorged pelvic veins due to reflux within ovarian and iliac veins. Though there is a relative paucity of randomized data on the outcomes of pelvic congestion syndrome treated with embolization, it is notable that multiple prospective single-arm observational studies have shown significant symptom improvement following the procedure, and that there are no viable alternative procedures that manage the symptoms related to vein incompetence. Specifically, there are no medical management or open surgical alternatives.
Experimental/Investigational · 2023 · IMR EI23-40386

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for a hysterectomy for treatment of the enrollee’s pelvic pain. Findings: The physician reviewer found that this patient presents with a history of chronic left lower quadrant abdominal pain. Initial examination findings were suggestive of neuropathic pain especially in the absence of significant pelvic findings on examination and imaging. After an MRI revealed some prominent pelvic veins, a CT described them as mildly prominent bilateral adnexal veins, which is not a rare incidental finding.
Medical Necessity · 2017 · IMR MN17-27001
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a laparoscopically assisted vaginal hysterectomy with salpingo-oophorectomy.Laparoscopic-assisted vaginal hysterectomy is considered definitive treatment for abnormal uterine bleeding and potentially may alleviate symptoms of pelvic pain. That said, hysterectomy is not the first-line treatment for these chief complaints in the setting of normal uterine pathology without an obvious source of pain. Typically, providers will consider performing a hysterectomy when there is a predominant uterine pain component by history and/or examination and the patient has exhausted a large number of other multimodal treatments.
Medical Necessity · 2021 · IMR MN21-35498

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving pelvic congestion syndrome, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Fighting a denial for pelvic congestion syndrome? Use the California record to prepare.

Explain my denial — freeStart my appeal · $39